Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two-Thirds Of Hepatitis C Patients Can See A Cure In Half The Time

15.09.2011
Response-guided treatment with drug telaprevir can be shortened to six months for many, says research published in New England Journal of Medicine

Treatment with a telaprevir-based combination regimen for hepatitis C – heretofore a chronic, destructive and difficult to manage disease – effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

Telaprevir, a drug approved for use against hepatitis C in May, inhibits replication of virus. This anti-viral drug and a similar medication called boceprevir have nearly doubled the number of patients with sustained response. Among patients treated with teleprevir, pegylated interferon and ribavirin in the new study, 72 percent were cured of their hepatitis C.

This study shows that two-thirds of patients can be cured in half the time: Patients who are clear of the virus within the first four to 12 weeks of therapy effectively can cut their treatment time from 48 weeks to six months. Besides the considerable benefits to patients of shorter treatment, these findings also show that response-guided therapy is a successful strategy.

“This means that rather than a one-size-fits-all approach, we can individualize treatment for patients based on their specific response to the drugs,” said Fred Poordad, MD, chief of Hepatology and Liver Transplantation at Cedars-Sinai and a senior author on the study. “Once you’re cured by these anti-viral drugs, you’re cured of hepatitis C completely. That’s a little known fact among the public – and even among physicians who don’t regularly treat liver disease.

Cedars-Sinai is one of the major research sites investigating new treatments for hepatitis C; the medical center is involved in developing most of these new compounds. Earlier this year, Dr. Poordad was the lead author of a study published in the New England Journal of Medicine on the anti-viral drug boceprevir, also an oral protease inhibitor. In that study, 1,097 patients with hepatitis C who had never been treated for the virus received standard treatment – pegylated interferon and ribavirin – for four weeks. Then, a third of the patients continued only on those drugs, while two other groups also received different durations of boceprevir. The boceprevir patients responded well, with 63 percent and 66 percent achieving sustained virus suppression – compared to 38 percent among patients taking only pegylated interferon and ribavirin.

According to the Centers for Disease Control, an estimated 3.2 million people in the United States have chronic hepatitis C virus infections. The disease is spread through virally infected blood, often by sharing of syringes or other equipment to inject drugs; prior to 1990, some infections can be attributed to blood transfusions. Some rare infections can be traced to medical procedures. Chronic hepatitis C is the leading cause of liver cancer and cirrhosis and is the chief reason for the need for liver transplants in the U.S. The disease is linked to as many as 10,000 deaths each year.

In the new telaprevir study, funded by Vertex Pharmaceuticals in Cambridge, Mass., a total of 540 patients were enrolled. They took a 12-week course of 750 milligrams of telaprevir three times a day in addition to therapy with pegylated interferon and ribavirin. Patients eligible for shortened treatment – meaning the virus was not detectable in the first month of treatment – were randomized to receive either 24 weeks or 48 weeks of treatment. The high cure rates among both groups showed that there was no benefit to additional treatment for early responders.

For patients, the shorter course of treatment means decreased costs, fewer side effects and less disruption to their daily lives, as this therapy requires intensive monitoring and laboratory visits.

Dr. Poordad has received research grants and served as an adviser and consultant for Vertex Pharmaceuticals, which makes telaprevir, and Merck, which makes boceprevir.

Sandy Van | Cedars-Sinai News
Further information:
http://www.cshs.org

Further reports about: Hepatitis Pharmaceuticals Two-Thirds anti-viral drug virus infection

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>